Adaptimmune Therapeutics
ADAP
ADAP was delisted on the 27th of October, 2025.
68 hedge funds and large institutions have $299M invested in Adaptimmune Therapeutics in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 16 reducing their positions, and 19 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 16
0.03% more ownership
Funds ownership: 11.02% → 11.04% (+0.03%)
15% less funds holding
Funds holding: 80 → 68 (-12)
25% less capital invested
Capital invested by funds: $397M → $299M (-$98.9M)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
85% less call options, than puts
Call options by funds: $6K | Put options by funds: $41K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$3.96M |
| 2 |
Millennium Management
New York
|
+$2.28M |
| 3 |
Man Group
London,
United Kingdom
|
+$1.37M |
| 4 |
Morgan Stanley
New York
|
+$874K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$839K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$4.03M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.26M |
| 3 |
A
Abingworth
London,
United Kingdom
|
-$1.44M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$754K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$748K |
ADAP Hedge Fund Activity: Q1 2019 in Review
68 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q1 2019, worth a combined $299M — down 25% from $397M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ADAP and 7 opened new positions — a net loss of 12 holders — while 16 trimmed existing stakes and 22 added.
The largest buyer was Matrix Capital Management Company, adding an estimated $3.96M. The largest seller was Foresite Capital Management II, exiting entirely with an estimated $4.03M sold.
- 68 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q1 2019, down from 80 in Q4 2018.
- Funds reported $299M of Adaptimmune Therapeutics stock for Q1 2019, down 25% quarter-over-quarter.
- 7 funds opened new Adaptimmune Therapeutics positions in Q1 2019 and 19 closed out, a net change of -12 holders.
- The largest Adaptimmune Therapeutics buyer in Q1 2019 was Matrix Capital Management Company, an estimated $3.96M added.
- The largest Adaptimmune Therapeutics seller in Q1 2019 was Foresite Capital Management II, an estimated $4.03M sold.
Based on aggregated 13F filings for Q1 2019.